Genetics for EDS Type VIIA (Arthrochalasia Type)
EDS type VIIA is caused by autosomal dominant mutations in the COL1A1 gene that result in skipping of exon 6, leading to defective removal of the N-propeptide from type I procollagen. 1
Genetic Basis and Molecular Mechanism
EDS type VIIA (arthrochalasia type) results from mutations affecting the COL1A1 gene that specifically disrupt the processing of type I procollagen. The mutations typically involve:
- Splice-junction mutations that cause exon 6 skipping 1
- Genomic deletions involving exon 6 1
- These defects prevent proper cleavage of the N-propeptide, resulting in structurally abnormal collagen fibrils 2
The molecular consequence is retention of N-propeptides in type I procollagen molecules, which fundamentally disrupts collagen fibril assembly and leads to the characteristic severe connective tissue fragility 2.
Inheritance Pattern
Autosomal dominant inheritance is the rule for EDS type VIIA 1. This means:
- A single mutated copy of COL1A1 is sufficient to cause disease
- Each offspring of an affected parent has a 50% chance of inheriting the condition
- Many cases represent de novo (new) mutations rather than inherited variants 1
Important Clinical Caveat
The severity of EDS type VIIA tends to be more pronounced than type VIIB (which involves COL1A2). COL1A1 mutations produce the most severe phenotypic effects, while COL1A2 mutations, regardless of location, primarily manifest with congenital hip dislocation and joint instability 1.
Recommended Genetic Testing Approach
Molecular genetic testing is indicated when clinical features suggest arthrochalasia-type EDS and should follow this algorithm 3:
- First-line testing: Targeted sequencing of COL1A1 exon 6 and flanking splice junctions
- If negative: Whole exome sequencing or clinical exome sequencing to identify deletions or atypical mutations 4
- Confirmatory biochemical studies: Analysis of procollagen processing can demonstrate persistence of pN-collagen (collagen retaining N-propeptides) 2
Testing Timing Considerations
- Prenatal diagnosis is possible when there is a known familial mutation 2
- Neonatal testing is critical because early diagnosis has significant implications for preventing physical disability through appropriate management of joint instability 2
Genetic Counseling Recommendations
Genetic counseling should address these specific points:
For Affected Individuals
- 50% recurrence risk for each pregnancy if the parent carries the mutation
- Variable expressivity: Even within families with the same mutation, severity can differ
- De novo mutations: If neither parent is affected, the recurrence risk for future siblings is low (though germline mosaicism remains a theoretical possibility)
Key Counseling Points for Management
- Congenital bilateral hip dislocation is a hallmark feature that requires immediate orthopedic intervention 2
- Progressive joint instability affecting nearly all joints can lead to severe disability; achieving and maintaining mobility is the greatest long-term challenge 2
- Fractures occur in some patients, consistent with altered mineral deposition on abnormal collagen fibrils in bone 1
- Hypotonia decreases with age and facial dysmorphism becomes less distinct, which can complicate diagnosis in older individuals 2
Differential Diagnosis Pitfalls
The significant neonatal hypotonia may mislead clinicians toward neuromuscular diagnoses rather than connective tissue disorders 2. Maintain high suspicion for EDS type VIIA in any neonate presenting with:
- Severe hypotonia
- Congenital bilateral hip dislocation
- Generalized joint hypermobility
- Distinct facial features (in infancy)
Genetic confirmation through COL1A1 mutation analysis is essential to distinguish EDS type VIIA from other hypermobility syndromes and to provide accurate prognostic information and family planning guidance 2, 3.